Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB.LN) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology.
Read more at globenewswire.com